European Marketing Authorization For Abilify - For Severe Manic Episodes In Bipolar I Disorder

On April 8, 2008, the European Commission made a decision to allow thedrug ABILIFY (aripiprazole) to be marketed. ABILIFY treats moderate tosevere manic episodes for patients with Bipolar I Disorder and it isdesigned to prevent new manic episodes in patients who experiencepredominately manic episodes.

AstraZeneca Announces First Presentation Of Pivotal SEROQUEL XR TM Bipolar Studies

New pivotal trial data from two clinical studies with SEROQUEL XR™ (quetiapine fumarate) once daily Extended Release Tablets were presented today at the Eighth International Review of Bipolar Disorder (IRBD) Conference in Copenhagen, Denmark..

Supplemental New Drug Application For RISPERDAL R CONSTA R Submitted To The FDA For The Treatment Of Frequently Relapsing Bipolar Disorder

Alkermes, Inc. (NASDAQ: ALKS) announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a Supplemental New Drug Application (sNDA) for RISPERDAL CONSTA [(risperidone) Long-Acting Injection] to the U.

Problems Identified With Diagnosis Of Bipolar Disorder

A new study by Rhode Island Hospital and Brown University researchers reports that fewer than half the patients previously diagnosed with bipolar disorder received a diagnosis of bipolar disorder based on a comprehensive, psychiatric diagnostic interview - -the Structured Clinical Interview for DSM-IV (SCID).

ABILIFY R aripiprazole Receives Expanded Indications For Maintenance Treatment In Pediatric Patients With Bipolar Disorder And Schizophrenia

Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that ABILIFY (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia. ABILIFY is now indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in pediatric patients (aged 10-17) and maintenance treatment of Schizophrenia in adolescents (aged 13-17).

FDA Approves Astrazeneca's Seroquel For Maintenance Treatment In Bipolar Disorder

AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL (quetiapine fumarate) for the maintenance treatment of patients with bipolar I disorder, as adjunct to lithium or divalproex. SEROQUEL is approved by the FDA for the treatment of schizophrenia, and is also the only single agent approved by the FDA for the treatment of both depressive episodes in bipolar disorder and acute manic episodes associated with bipolar I disorder1, 2.

Benefits Of Omega 3s Still Unclear For Bipolar Disorder

Despite intriguing findings that omega 3 fatty acid supplements could alleviate depression symptoms, there is still not enough evidence to say whether omega 3s are useful treatments for people with bipolar disorder, according to a review of recent studies.

Perceptual Switch Rates With Ambiguous Structure-from-motion Figures In Bipolar Disorder

Most people believe that the way we see things is affected by how we feel emotionally. Does our mood really change what we see or do individuals with certain genetic traits always tend to see things differently, regardless of their mood? Earlier research suggested that people with bipolar mood disorder might alternate their perception more slowly when looking at ambiguous figures.

Alcohol Dependence May Respond To Aripiprazole, Treatment For Bipolar Disorder And Schizophrenia.

* Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. * A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol.

Overview Of Asenapine Data From Olympia Trial Program Presented At American Psychiatric Association Annual Meeting

Schering-Plough Corporation (NYSE: SGP) announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the American Psychiatric Association in Washington, D.C., May 3-8. Data from the studies, involving patients with bipolar I disorder and schizophrenia, were presented in two oral presentations (Abstracts # 44 and # 80).